Needham Downgrades Day One Biopharmaceuticals (DAWN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DAWN Hot Sheet
Price: $21.53 --0%
Rating Summary:
3 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 3
Rating Summary:
3 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 3
Join SI Premium – FREE
Needham analyst Ami Fadia downgraded Day One Biopharmaceuticals (NASDAQ: DAWN) from Buy to Hold.
For an analyst ratings summary and ratings history on Day One Biopharmaceuticals click here. For more ratings news on Day One Biopharmaceuticals click here.
Shares of Day One Biopharmaceuticals closed at $12.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Downgrades Arthur J. Gallagher (AJG) to Market Perform, 'Taking Profits'
- Oppenheimer on Bloom Energy Corp. (BE) 1GW MOU from Monday: 'We would expect shares to maintain modest gains'
- Raymond James on Airbnb Inc. (ABNB) into Earnings: 'AI Founder Mode Firing Up as Fundamental Strength Likely Persists'
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & Company, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
